[Assessment of soluble E selectin levels in patients with Graves' disease and thyroid orbitopathy].
The aim of this study is to evaluate serum concentrations of sELAM-1 in patients with Graves' orbitopathy (GO). We studied levels of soluble form of E selectin -1 in patients with euthyroid progressive GO (group I) and euthyroid stable GO (group II), hyperthyroid Graves' disease (GD) without GO (group III) and in healthy controls (group IV). sELAM-1 levels were measured by ELISA method. The highest serum levels of sELAM-1 were found in group III. Mean sELAM-1 concentrations in patients with progressive and stable GO were slightly lower than those in group III patients. The sELAM-1 serum concentrations in group I and II were comparable, nearly the same despite the different clinical picture of the disease in both groups. Mean serum concentrations of sELAM-1 decreased significantly during treatment of progressive GO, parallel to the improvement of the eye changes. In conclusion, sELAM-1 concentrations do not reflect the degree of GO activity. A significant decrease in sELAM-1 concentrations are associated with the efficient outcome of treatment. Increased sELAM-1 levels seem to result form both GO and GD.
Kulig
Grzegorz
G
Klinika Endokrynologii, Nadciśnienia, Tetniczego i Chorób Przemiany Materii, Pomorskiej Akademii Medycznej w Szczecinie. grzegorz.kulig@wp.pl
Pilarska
Krystyna
K
Kulig
Jolanta
J
Robaczyk
Maciej
M
Gromniak
Elwira
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D019040:E-Selectin / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005094:Exophthalmos / Q000150:complications / Q000503:physiopathology; D005260:Female; D006111:Graves Disease / Q000097:blood* / Q000150:complications / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013961:Thyroid Gland / Q000503:physiopathology*
D019040:E-Selectin